Shift 1: From Regulatory Compliance to Strategic Value Creation
Historically, Regulatory Affairs has focused on obtaining and maintaining marketing authorisations.
Tomorrow, Regulatory Affairs will influence portfolio prioritisation, investment decisions and lifecycle planning.
Questions such as:
- Is this asset likely to benefit from future incentives?
- Does our development strategy support future access expectations?
- How resilient is the regulatory value proposition?
will increasingly be discussed long before submission.
Regulatory strategy becomes part of business strategy.
Shift 2: From Sequential Functions to Integrated Decision-Making
The traditional development model has often followed a linear path: Clinical, then Regulatory, then Market Access, then Commercial.
The new framework makes this approach increasingly unsustainable.
Evidence generation, comparator selection, HTA expectations and regulatory requirements are becoming progressively interconnected.
Companies will need earlier collaboration between:
- Regulatory Affairs
- Clinical Development
- Medical Affairs
- Market Access
- Supply Chain
- Quality
Competitive advantage will depend on organisational integration rather than functional excellence alone.
Shift 3: From Protecting Exclusivity to Earning Incentives
One of the most significant conceptual changes introduced by the reform is that regulatory incentives become increasingly conditional.
Protection is no longer simply granted.
It must increasingly be earned through:
- addressing unmet medical needs
- generating meaningful evidence
- supporting timely patient access
- meeting broader public health objectives
This fundamentally changes lifecycle strategy.
Portfolio decisions should therefore include regulatory scenario planning much earlier than they traditionally have.
Shift 4: From Supply Management to Supply Resilience
Medicine shortages have become a strategic priority for European policymakers.
Consequently, supply continuity is no longer viewed solely as an operational responsibility. It is becoming a regulatory expectation.
Companies should anticipate:
- greater scrutiny of supply risks
- stronger governance requirements
- closer interaction between Regulatory Affairs and Operations
Resilient supply chains are becoming part of the overall product value proposition.
Shift 5: From Responding to Regulation to Anticipating Regulation
Perhaps the biggest change is cultural.
Historically, many organisations have interpreted regulation once legislation had been adopted.
The Pharmaceutical Package requires companies to anticipate change years before implementation.
This demands:
- continuous regulatory intelligence
- strategic scenario planning
- cross-functional governance
- executive-level awareness of regulatory risks
Preparation becomes a competitive advantage.
The transition period before the new legislation becomes fully applicable may create the impression that there is still time to prepare.
In reality, many of the decisions that will determine future competitiveness are already being made today.
The companies that will benefit most from the new regulatory environment are not necessarily those that react faster once the legislation applies. They are those that start asking different strategic questions now.
1. Are We Still Prioritising Our Portfolio Using Yesterday’s Criteria?
Traditionally, portfolio decisions have been driven by scientific opportunity, commercial potential and development risk.
The EU Pharmaceutical Package introduces additional variables that may significantly influence long-term value:
- eligibility for regulatory incentives
- evidence expectations
- access considerations
- supply resilience
The question is no longer simply “Can we develop this product?”
It becomes: “Will this product create sustainable regulatory and commercial value under tomorrow’s framework?”
2. Are Regulatory Decisions Being Taken Early Enough?
In many organisations, Regulatory Affairs still enters the conversation once development strategy has largely been defined.
Yet many of the most important regulatory risks originate much earlier:
- study design
- comparator selection
- endpoint strategy
- evidence generation
- global development planning
The issue is not whether Regulatory Affairs participates: it is when.
3. Is Our Organisation Optimised for a World That No Longer Exists?
Many pharmaceutical companies continue to operate through highly specialised functions:
- Clinical
- Regulatory
- Market Access
- Supply
Each highly competent. Each largely independent.
The Pharmaceutical Package encourages a different operating model.
The competitive advantage will increasingly come from the quality of interaction between functions, rather than the excellence of each function individually.
4. Are We Measuring Regulatory Success Correctly?
Historically, regulatory performance has often been measured by operational metrics:
- submission timelines
- approval success rates
- compliance indicators
These remain essential.
But future success may depend equally on different indicators:
- quality of early regulatory influence
- alignment between regulatory and access strategy
- contribution to portfolio decisions
- organisational readiness
The scope of Regulatory Affairs is expanding: its metrics should evolve accordingly.
5. Are We Preparing for Compliance, or for Competitive Advantage?
Perhaps the most important question is also the simplest.
Every company will eventually comply with the new legislation.
The real differentiator is whether organisations use the transition period merely to update procedures, or to rethink how regulatory strategy contributes to business performance.
The Pharmaceutical Package creates an opportunity to redesign decision-making, not just documentation.
